This Slide: #77 of 100 |
Slide #77. Abbott Laboratories — IDEV Technologies
Acquirer:
Abbott Laboratories (NYSE:ABT)
Acquiree:
IDEV Technologies
Details:
RiverVest Venture Partners announced today that Abbott Laboratories is acquiring RiverVest medical device portfolio company IDEV Technologies for $310 million. With the sale of IDEV, life sciences venture capital firm RiverVest has successfully exited six portfolio companies since 2011, generating total acquisition proceeds of more than $1.5 billion, with more than $120 million of these proceeds going to RiverVest funds.
Abbott Laboratories is engaged in the discovery, development, manufacture, and sale of a line of health care products. Co. has four segments: Established Pharmaceutical Products, which includes a line of generic pharmaceuticals; Diagnostic Products, which includes a line of diagnostic systems and tests; Nutritional Products, which includes a line of pediatric and adult nutritional products; and Medical Devices, which includes a line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
Abbott Laboratories SEC Filing Email Alerts Service
Open the ABT Page at The Online Investor »
|
Open the ABT Page at The Online Investor (in a new window) »
Free ABT Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (3.47 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: ABT Stock Forecast Based on Zacks ABR data; powered by Xignite |